<p>, /PRNewswire/ --</p>
<p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 1 月 16 日至 2025 年 9 月 12 日期间（包括这两个日期）购买了 aTyr Pharma, Inc.（纳斯达克：ATYR）普通股的投资者注意 2025 年 12 月 8 日的重要首席原告截止日期。</p>
<p>那么：如果您在该期间购买了 aTyr Pharma 的普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
<p>接下来该做什么：要加入 aTyr Pharma 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=46109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任首席原告，必须在 2025 年 12 月 8 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
<p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。这些律师事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
<p>案件详情：根据投诉，被告向投资者提供了极为积极的声明，同时传播虚假和误导性陈述和/或隐瞒有关 Efzofitimod 疗效的重大不利事实，特别是该药物使患者完全减少类固醇使用的能力。</p>
<p>当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
<p>要加入 aTyr Pharma 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=46109，拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
<p>尚未认证集体。直到集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
<p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
<p>律师广告。之前的结果并不保证类似的结果。</p>
<p>联系信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>罗森律师事务所</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>纽约，NY 10016</p>
<p>电话：(212) 686-1060</p>
<p>免费电话：(866) 767-3653</p>
<p>传真：(212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>来源：罗森律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9REM0MjAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgyMDU5UFJfTkVXU19VU1BSX19fX19EQzQyMDE5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9REM0MjAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgyMDU5UFJfTkVXU19VU1BSX19fX19EQzQyMDE5"/></p>

LIFE

<p>罗森律师事务所宣布对 aTyr Pharma, Inc. 提起证券欺诈的集体诉讼。2025 年 1 月 16 日至 2025 年 9 月 12 日期间购买股票的投资者可以加入诉讼。担任首席原告的截止日期为 2025 年 12 月 8 日。罗森律师事务所以其在证券集体诉讼中的成功而闻名，鼓励投资者选择经验丰富的律师。诉讼声称 aTyr Pharma 对 Efzofitimod 的有效性做出了虚假陈述，导致投资者损失</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the &#34;Class Period&#34;), of the important December 8, 2025 lead plaintiff deadline.</p>
<div class="lb-trans"><p>原因：罗森律师事务所是一家全球投资者权益律师事务所，提醒在 2025 年 1 月 16 日至 2025 年 9 月 12 日期间（包括这两个日期）购买了 aTyr Pharma, Inc.（纳斯达克：ATYR）普通股的投资者注意 2025 年 12 月 8 日的重要首席原告截止日期。</p>
</div><p>So what: If you purchased aTyr Pharma common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那么：如果您在该期间购买了 aTyr Pharma 的普通股，您可能有权在不支付任何自付费用或成本的情况下，通过风险代理安排获得赔偿。</p>
</div><p>What to do next: To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下来该做什么：要加入 aTyr Pharma 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=46109 或拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。集体诉讼已经提起。如果您希望担任首席原告，必须在 2025 年 12 月 8 日之前向法院提出申请。首席原告是代表其他集体成员指导诉讼的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>为什么选择罗森律师事务所：我们鼓励投资者选择在领导角色上有成功记录的合格律师事务所。通常，发布通知的律师事务所没有可比的经验、资源或任何有意义的同行认可。这些律师事务所中的许多并不真正进行证券集体诉讼，而只是作为中介，转介客户或与实际进行诉讼的律师事务所合作。在选择律师时要明智。罗森律师事务所代表全球投资者，专注于证券集体诉讼和股东衍生诉讼。罗森律师事务所曾在当时获得针对中国公司的最大证券集体诉讼和解。该事务所于 2017 年被 ISS 证券集体诉讼服务评选为证券集体诉讼和解数量第一。自 2013 年以来，该事务所每年均排名前四，并为投资者追回了数亿美元。仅在 2019 年，该事务所就为投资者获得了超过 4.38 亿美元的赔偿。在 2020 年，创始合伙人 Laurence Rosen 被 law360 评选为原告律师界的巨头。该事务所的许多律师已获得 Lawdragon 和 Super Lawyers 的认可。</p>
</div><p>Details of the case: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning the efficacy of Efzofitimod, particularly, the drug's capability to allow a patient to completely taper their steroid usage.</p>
<div class="lb-trans"><p>案件详情：根据投诉，被告向投资者提供了极为积极的声明，同时传播虚假和误导性陈述和/或隐瞒有关 Efzofitimod 疗效的重大不利事实，特别是该药物使患者完全减少类固醇使用的能力。</p>
</div><p>When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>当真实情况进入市场时，诉讼声称投资者遭受了损失。</p>
</div><p>To join the aTyr Pharma class action, go to https://rosenlegal.com/submit-form/?case_id=46109 call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 aTyr Pharma 集体诉讼，请访问 https://rosenlegal.com/submit-form/?case_id=46109，拨打无障碍电话 866-767-3653 联系 Phillip Kim 律师，或发送电子邮件至 [email protected] 获取有关集体诉讼的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未认证集体。直到集体被认证之前，除非您聘请律师，否则您不受律师的代表。您可以选择自己选择的律师。您也可以保持缺席集体成员的身份，此时不采取任何行动。投资者分享任何潜在未来赔偿的能力并不依赖于担任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>关注我们的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/.</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律师广告。之前的结果并不保证类似的结果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>联系信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>罗森律师事务所</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>纽约，NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>电话：(212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免费电话：(866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>传真：(212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>来源：罗森律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMjA4Jk5ld3NJdGVtSWQ9REM0MjAxOSZUcmFuc21pc3Npb25fSWQ9MjAyNTEyMDgyMDU5UFJfTkVXU19VU1BSX19fX19EQzQyMDE5" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC42019&amp;Transmission_Id=202512082059PR_NEWS_USPR_____DC42019&amp;DateId=20251208"/></p>

ATYR 最后期限：遭受损失的 ATYR 投资者有机会主导 aTyr Pharma, Inc.的证券欺诈诉讼